1. Introduction {#sec1}
===============

Sarcomas are cancers of mesenchymal origin \[[@B1]\] that comprise about 1% of adult malignancies. Leiomyosarcomas are derived from smooth muscle cells. At most primary sites, other than the uterus or gastrointestinal tract, leiomyosarcomas are likely to originate from the tunica media of blood vessels. However, it has been postulated that primary leiomyosarcoma of the bone might also develop through advanced myogenic metaplasia of a sarcoma originating from fibroblastic tissue \[[@B2]\]. The disease typically occurs in the 5th to 6th decades of life, with women being affected more than men (2 : 1). This gender distribution may reflect the proliferation of smooth muscle that can occur in response to estrogen \[[@B3]\].

Because sarcomas tend to respond poorly to standard chemotherapy, they have no good treatment options beside total excision with wide margins. However, the gradual replacement of the highly toxic conventional cancer chemotherapy (comprising nonspecific antiproliferative agents) with molecularly targeted drugs, which was initiated with the market entry of neutralizing antibodies and small molecule kinase inhibitors in 1997 (Rituxan) and 2001 (Gleevec), respectively, has opened the possibility to tailor drug treatment to particular tumors. Yet, this transition has also necessitated the molecular characterization of the lesions that are causative for the transformation of healthy cells to cancerous cells because drugs need to be matched with the underlying carcinogenic defect to be effective. Here, we take a sarcoma through a comprehensive molecular analysis that applies multiple screening techniques, with the goal to identify the disease-causing defects as well as potential drug targets.

2. Materials and Methods {#sec2}
========================

2.1. Patient and Tissues {#sec2.1}
------------------------

A 52-year-old female patient underwent surgery for a recurrent sarcoma. Samples of skeletal muscle, bone, and tumor were obtained postsurgery.

2.2. DNA Exome Sequencing {#sec2.2}
-------------------------

1 *μ*g of dsDNA determined by Invitrogen Qubit high sensitivity spectrofluorometric measurement was sheared by sonication to an average size of 300 bp on a Diagenode Bioruptor. Automated library construction was performed on an IntegenX Apollo324 which size-selects fragments by double-SPRI binding with different concentrations of PEG for a high cut and a low cut. Each library can be fitted with one of 48 adapters, each containing a different 6-base molecular barcode for high level multiplexing. After 12 cycles of PCR amplification, 1 *μ*g of genomic library was recovered for exome enrichment using the NimbleGen EZ Exome V2 kit. Enriched libraries were sequenced on an Illumina HiSeq2000, generating around 32 million high quality paired end reads of 100 base each or 6.4 GB of usable sequence per sample. The analysis methods utilize the Broad Institute\'s Genome Analysis Toolkit (GATK) and follow a pipeline previously described \[[@B4]\], along with published modifications (<http://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_Toolkit>). The analysis comprises aligning the reads that pass Illumina Chastity Filter with the Burrows-Wheeler Aligner (BWA) \[[@B5]\]. For each sample, Picard\'s MarkDuplicates are used to flag reads that appear to be artifacts of PCR bias. All reads that overlap known or putative indels are realigned. All base quality scores are recalibrated to the empirical error rate derived from nonpolymorphic sites. The GATK\'s Unified Genotyper module is used to call variant sites (both single nucleotide and small indel) in all samples simultaneously. Finally, the SNV calls are filtered using the variant quality score recalibration method \[[@B4]\]. Indel calls were filtered with a set of hard filters, as there are not enough indels in an exome to use the Gaussian method.

2.3. RNAseq {#sec2.3}
-----------

Tissue samples were homogenized in RNazol RT (MRC) with a manual homogenizer and stored on ice until extraction. The RNA isolation was performed according to the manufacturer\'s instructions.

The Ovation RNA-Seq FFPE system (NuGen) was used to initiate amplification at both 3′ end as well as randomly throughout the transcriptome in the sample. 100 ng of total RNA with RIN \< 5.0 was converted into a library of template molecules suitable for subsequent cluster generation and sequencing by Illumina HiSeq. Total RNA was reverse transcribed and converted to double stranded cDNA with a unique DNA/RNA heteroduplex at one end. NuGEN\'s Ribo-SPIA technology was used for isothermal amplification resulting in the rapid generation of cDNA with a sequence complementary to the original mRNA. The cDNA was then double stranded and fragmented to 200 bp using Covaris S2, and a sequencing library was generated using Illumina\'s TruSeq DNA Sample Prep Kit V2 according to standard protocols. The cDNA library was enriched by a limited number of 10 PCR cycles, validated using an Agilent 2100 Bioanalyzer, and quantitated using the Quant-iT dsDNA HS Kit (Invitrogen). Two individually indexed cDNA libraries were pooled and sequenced on Illumina HiSeq to get a minimum of 90 million reads. Libraries were clustered onto a flow cell using Illumina\'s TruSeq SR Cluster Kit v2.5 and sequenced 50 cycles using TruSeq SBS Kit-HS on HiSeq. The obtained sequence reads were aligned to the genome by using the standard Illumina sequence analysis pipeline.

2.4. Protein-DNA Array {#sec2.4}
----------------------

Tissues were ground between frosted glass slides and then incubated with Collagenase and Dispase in cell culture medium at 37°C for 45 minutes to release individual cells. These cells were collected after passing the samples through a strainer and centrifugation. Nuclear extracts and cytosol were prepared using a kit from Active Motif. After protein determination, DNA binding of the nuclear extracts was assessed with the Combo protein-DNA array (Panomics). Signal intensity was measured with the software MetaMorph.

2.5. Western Blotting {#sec2.5}
---------------------

For the analysis of individual proteins, tissues were homogenized in RIPA buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate) using a handheld, battery-operated homogenizer. 10 *μ*g lysates were loaded per lane and electrophoresed on 10% SDS-polyacrylamide minigels with reducing, denaturing sample buffer. The separated proteins were transferred to PVDF membranes and probed with antibody O-17 (IBC) to the C-terminus of osteopontin and anti-HCAM to the cytoplasmic domain of CD44 (Santa Cruz) and to STAT3 and phospho-STAT3 (Cell Signaling Technology). Antitubulin serves as a loading control.

2.6. 2D Gel Electrophoresis and Mass Spectrometry {#sec2.6}
-------------------------------------------------

The tumor and muscle samples were diluted to 4 and 1 mg/mL in 1 : 1 diluted SDS Boiling Buffer : Urea Sample Buffer before loading (the bone sample was ethanol precipitated and redissolved to 4 and 1 mg/mL in 1 : 1 diluted SDS Boiling Buffer : Urea Sample Buffer). Two-dimensional electrophoresis was performed according to the carrier ampholine method of isoelectric focusing \[[@B6], [@B7]\] by Kendrick Labs, Inc. Isoelectric focusing was carried out in glass tubes of inner diameter 2.3 mm using 2% pH 4--8 Servalytes (Serva, Germany) for 9600 volt-hours. 1 *μ*g (Coomassie stain) or 50 ng (silver stain) of an IEF internal standard, tropomyosin, was added to each sample. This protein migrates as a doublet with lower polypeptide spot of MW 33,000 and pI 5.2; its position is marked by an arrow on the stained gels. The enclosed tube gel pH gradient plot for this set of ampholines was determined with a surface pH electrode.

After equilibration for 10 min in buffer "O" (10% glycerol, 50 mm dithiothreitol, 2.3% SDS, and 0.0625 M Tris, pH 6.8), each tube gel was sealed to the top of a stacking gel that was on top of a 10% acrylamide slab gels (0.75 mm thick). SDS slab gel electrophoresis was carried out for about 4 hours at 15 mA/gel. The following proteins (Sigma Chemical Co.) were used as molecular weight standards: myosin (220,000), phosphorylase A (94,000), catalase (60,000), actin (43,000), carbonic anhydrase (29,000), and lysozyme (14,000). These standards appear along the basic edge of the Coomassie blue R-250 stained or silver-stained \[[@B8]\] 10% acrylamide slab gel. The gels were dried between sheets of cellophane paper with the acid edge to the left. Each of the gels was overlaid with a transparent sheet for labeling polypeptide spot differences without marking the original gel (Kendrick Labs).

2.7. Polymorphism Analysis {#sec2.7}
--------------------------

We obtained 22 formalin-fixed, paraffin-embedded leiomyosarcoma specimens (stroma and paraffin had been removed from unstained slides under microscopic examination) through the Department of Pathology, University of Cincinnati. DNA was extracted with the AllPrep DNA/RNA FFPE kit (Qiagen). We purchased 7 frozen leiomyosarcoma tissues from Creative Bioarray and extracted DNA with the AllPrep DNA/RNA Mini Kit (Qiagen). One blood sample from a leiomyosarcoma patient was received from the University of Cincinnati Tissue Bank. Polymorphisms in FAF1 were analyzed in the DNA using a custom TaqMan assay with the probe ACACCAGATTTGCCACCACCTTCATCATCT \[A/G\] GTCATGCTGGGTAAGTTGTTTATATTTCCTG. A TaqMan assay with an existing probe for position −443 in the osteopontin promoter served as a reference assay. 34 breast cancer DNA samples served as nonsarcoma control. The assay was performed by the CCHMC DNA core.

3. Results {#sec3}
==========

3.1. Patient History {#sec3.1}
--------------------

In 1998, the patient was diagnosed with high grade, stage IIb osteogenic sarcoma of the right femur, which was extracompartmental. Upon resection the lesion had a size of 9.5 × 3 × 4 cm ([Figure 1](#fig1){ref-type="fig"}). The tumor was assessed as stage T2NxMx, grade III, characterized as hypercellular; it showed marked cytologic atypia and a high mitotic rate. Histologic features included anaplasia, pleomorphism, numerous abnormal mitoses, numerous giant cells, and osteoid production with focal calcifications.

In 2012, a CT scan, done because of hip pain, revealed a 4.3 × 3.4 × 3.1 cm lytic mass in the superior right acetabulum, grossly stable in size and configuration. There was diffuse osteopenia involving the right femoral head and neck with diffuse atrophy of the right pelvic girdle musculature. Periostitis and cortical interruption were associated with this lesion.

The postsurgical pathology report identified the 5.7 × 5.5 × 4.9 cm mass as a high grade leiomyosarcoma, stage pT2bpNx. Whereas a bone scan revealed intense activity in the left seventh rib, a follow-up chest CT provided no indication of pulmonary masses, mediastinal or hilar lymphadenopathy, enlargement of axillary nodes, or pleural effusion, implying stage M0. The mitotic rate was 70%, with 60% necrosis. The tumor caused extensive bone destruction and involvement of adjacent tissue. Histologically, the tumor cells stained positively for smooth muscle actin. They were also positive for CD68 and displayed diffuse positive staining for vimentin but were negative for CD117, pancreatin, S-100, and CD34.

Seven months after the surgery, the patient received a PET-MRI scan for pain, which revealed six metastatic lesions, including both lungs and multiple ribs. She was put on three 21-day cycles of Gemzar (days 1 and 8), Taxotere (day 8), and Neulasta (beginning on day 9) but was unable to continue past the first cycle due to hospitalizations for continued and problematic wound infections at the surgical lung biopsy sites.

3.2. DNA Exome Sequence {#sec3.2}
-----------------------

Exome sequencing of the genomic DNAs for tumor, muscle, and bone identified 65546 potential sequence variants. Filtering yielded 46 likely somatic mutations in the tumor ([Table 1](#tab1){ref-type="table"}), of which 7 (affecting EIF4A1, EPHA3, FAF1, IPO8, KIAA1377, LIMCH1, and NIPBL) were confirmed in the RNASeq results. FAF1 associates with FAS and enhances apoptosis mediated through this receptor \[[@B9]\]. The point mutation S181G ([Figure 2](#fig2){ref-type="fig"}) could cause a loss of function in FAF1 and lead to transformation via antiapoptosis.

3.3. RNA Analysis {#sec3.3}
-----------------

Expectedly, the gene expression patterns, according to RNASeq, were very different among tumor, muscle, and bone. The cancer contained several gene products that were overexpressed compared to both muscle and bone (Tables [2](#tab2){ref-type="table"}(a) and [2](#tab2){ref-type="table"}(b)). Among the top 30 changes in the tumor/muscle and tumor/bone comparisons, 13 were identical ([Table 2(c)](#tab2){ref-type="table"}). It is implied that these gene products are quite unique for the tumor and likely contribute to its pathogenesis. This notion is supported by the upregulation of the smooth muscle gene Ano4, which corroborates the leiomyosarcomatous nature of the cancer. When limiting the analysis to genes expressed at least at the level of 1 unit, the 17 genes overexpressed in the tumor/muscle and tumor/bone comparisons contain several extracellular matrix proteins, implying an active remodeling of the tumor microenvironment ([Table 2(d)](#tab2){ref-type="table"}). By contrast, none of the underexpressed gene products in the tumor/muscle comparison matched the tumor/bone comparison (not shown).

Of note, the RNA level of IGF2BP1 (IMP-1, CRD-BP, and ZBP-1) is highly upregulated in the tumor compared to muscle as well as bone. IGF2BP1 is a RNA-binding factor that affects mRNA nuclear export, localization, stability, and translation. It regulates mRNA stability during the integrated cellular stress response in stress granules. IGF2BP1 is a transcriptional target of the WNT pathway, which is negatively regulated by intact FAF1 and may be unregulated by FAF1^S181G^. The IGF system has been linked to sarcoma pathogenesis \[[@B10]\] and may play a role in this specific cancer. Other IGF family members with increased RNA message levels in this tumor (compared to muscle and bone) include IGFBPL1 (5-6-log~2~-fold), IGFL3 (6-7-log~2~-fold), and IGF2BP3 (2-6-log~2~-fold).

The identified point mutation in FAF1 may be pathogenetic for this cancer. FAF1 is a regulator of NF-*κ*B activation. It directly binds to RelA (P65), retaining it in the cytoplasm. It can also interact with IKK*β*, thus allowing for the I*κ*B-mediated degradation of the transcription factors P65 and P50 \[[@B11]\]. Consistently, the expression of regulators of the NF-*κ*B activation pathway is skewed in the tumor compared to muscle or bone ([Table 2(e)](#tab2){ref-type="table"}).

3.4. Transcription Factor Binding {#sec3.4}
---------------------------------

Protein/DNA arrays measure the binding activity of transcription factors. They comprise three basic steps. A set of biotin-labeled DNA binding oligonucleotides are preincubated with a nuclear extract of interest. The protein/DNA complexes are separated from the free probes. The probes in the complexes are then extracted and hybridized to prespotted membranes followed by HRP-based chemiluminescence detection. We made nuclear extracts from tumor, bone, and muscle and tested them for DNA binding activity. Binding that was induced in cancer, but not in the normal tissues, was displayed by the transcription factors E2F1, AP3, LIII-BP, PAX6, ADD-1, and CCAC \[[@B32]--[@B37]\]. The CCAC binding activity is consistent with a muscle-derived tumor. E2F1 may associate with the WNT pathway-induced transcription factor LEF1, resulting in transcriptional derepression of E2F1 \[[@B12]\]. Likely constitutive transcription factors that are active in all 3 tissues comprise AhR/Amt, GATA1, GATA2, GATA1/2, HIF1, and HOXD8/9/10 ([Figure 3](#fig3){ref-type="fig"}).

3.5. Protein Analysis {#sec3.5}
---------------------

2D gel electrophoresis of the RIPA lysates from tumor, muscle, and bone showed very divergent patterns ([Figure 4(a)](#fig4){ref-type="fig"}). Two experienced analysts compared the protein pattern from the tumor with the protein pattern from either bone or muscle. Polypeptide spots that were unique to the gels from the tumor were outlined (spots unique to or relatively darker in the bone or muscle were not indicated). The labeled proteins were extracted for identification with mass spectrometry. This yielded several structural proteins, which may reflect modification of the cellular architecture under rapid growth. Transgelin-1 and transgelin-2 were abundant and corroborated the identity of the tumor as a leiomyosarcoma. Four calcium-binding proteins were highly expressed in the cancer. In addition, regulators of protein synthesis (40S ribosomal protein S12, glycine-tRNA ligase), protein modification (N-terminal fragment of heat shock protein HSP 90*α*, C-terminal fragment of protein disulfide isomerase), and protein degradation (*α*1-antitrypsin, proteasome activator complex subunit 2) were identified ([Figure 4(b)](#fig4){ref-type="fig"}). Of interest may be the C-terminal fragment of protein disulfide isomerase, which not only hydroxylates prolines in preprocollagen but also contributes to microsomal triglyceride transfer. It could be reflective of a skewed tumor metabolism. The protein analysis was corroborated by the mRNA levels ([Figure 4(d)](#fig4){ref-type="fig"}).

Cancer markers were tested according to Western blot ([Figure 4(c)](#fig4){ref-type="fig"}). The tumor, but not normal muscle, expressed the metastasis protein osteopontin and a single small form (\<75 kD) of CD44 that is likely the not alternatively spliced, standard form. Unexpectedly, while both tumor and muscle expressed comparably abundant amounts of STAT3, phosphorylation (reflective of activation) was present in the muscle but not in the tumor. The STAT3 pathway is associated with progression in several human cancers, and this is often reflected in STAT3 constitutive phosphorylation. The lack of phosphorylation in this case suggests that the leiomyosarcoma may not depend on the STAT3 pathway.

3.6. Pharmacogenetic Evaluation {#sec3.6}
-------------------------------

Predicting the sensitivity to anticancer drugs is a main goal of molecular analysis. For this, the over- or underexpression of genes for drug transport and metabolism is of key importance. Analysis of the RNASeq data for these groups of gene products identified a surprisingly large number of deregulations compared to muscle or bone (Tables [3](#tab3){ref-type="table"}(a) and [3](#tab3){ref-type="table"}(b)). Those alterations may affect choices for drug treatment. For example, the high levels of glutathione S-transferase may render carmustine, thioTEPA, cisplatin, chlorambucil, melphalan, nitrogen mustard, phosphoramide mustard, acrolein, or steroids ineffective. The overexpression of*N*-acetyltransferase may compromise 5-fluorouracil or taxol. The modest upregulation of only two export transporters (ABC-transporters), and specifically the lack of ABCB1 overexpression, is favorable for avoiding drug resistance.

3.7. Population Analysis {#sec3.7}
------------------------

The above-described results indicated that a FAF1 mutation, which replaces serine in position 181, thus preventing FAF1 phosphorylation and activation, may be a driver for leiomyosarcomagenesis. A custom TaqMan assay confirmed the presence of the somatic mutation in the patient. To assess whether this single nucleotide replacement is common in this type of cancer, we analyzed DNA from 29 leiomyosarcomas and 1 blood sample from a leiomyosarcoma patient. For comparison to nonsarcomatous tumors, 34 breast cancers served as a reference. None of them displayed a mutation in the same locus. By contrast, there was a distribution across all leiomyosarcomas in the osteopontin promoter position −443 (used as a reference), with 12 CC, 10 TC, and 9 TT.

4. Discussion {#sec4}
=============

The FAF1 mutation identified as the likely cause for the cancer under study gives room for an explanation of the sarcomatous transformation ([Figure 5](#fig5){ref-type="fig"}). DNA damage to mesenchymal cells occurs persistently in an oxidizing environment at 37°C. These insults are rarely transforming, and such an occurrence would trigger the initiation of programmed cell death in apoptosis-competent cells. Intact FAF1 associates with FAS and enhances apoptosis mediated through this receptor \[[@B9]\]. A loss of function in FAF1 could lead to transformation via antiapoptosis. Whereas the mutation S181G is not expected to disrupt the structure of the protein, this site does score high as a possible phosphorylation site for a number of kinases involved in DNA damage repair, supporting the hypothesis that the cancer cells containing this mutation have lost their ability to respond to transforming DNA damage with programmed cell death. FAF1 antagonizes WNT signaling by promoting *β*-catenin degradation in the proteasome \[[@B13]\], a function that may be lost after the point mutation. The elevated DNA binding activity of the protooncogenic transcription factor E2F1 (see [Figure 3](#fig3){ref-type="fig"}) could be caused by its interaction with LEF-1 \[[@B12]\], consecutive to persistent WNT signaling. The RNA level of IGF2BP1 (IMP-1), a stress-responsive regulator of mRNA stability, is highly upregulated in the tumor compared to muscle as well as bone (see [Table 2(c)](#tab2){ref-type="table"}). IGF2BP1 is a transcriptional target of the WNT pathway that regulates NF-*κ*B activity (see [Table 2(e)](#tab2){ref-type="table"}) and is antiapoptotic \[[@B14], [@B15]\]. IGF2BP1 may be upregulated as a consequence of mutated FAF1 not being able to suppress WNT signaling in this specific cancer. Of note, WNT pathway overactivity may not be required for transformation; rather the persistence of a WNT pathway signal due to the lack of a FAF1-mediated termination signal may suffice.

The role of WNT signaling in sarcoma has been subject to debate (e.g., \[[@B16]\]). In metastatic leiomyosarcoma, *β*-Catenin may accumulate in the nucleus despite a relatively weak expression of WNT \[[@B17]\]. This may be due to WNT signal activation via noncanonical ligands \[[@B18]\] or to *β*-Catenin binding the nuclear receptor NR4A2 and releasing it from the corepressor protein LEF-1 \[[@B19]\]. Of note, in the cancer under study here, the mRNA level of NR4A2 was overexpressed 10-fold compared to bone and 3-fold compared to muscle. The results from this study are consistent with the possibility that a lack of termination in the WNT signal, rather than its overactivation, could contribute to sarcomatous transformation. Such a mechanism may be reflected in an upregulation of downstream targets, even though overexpression of WNT pathway components is not detectable.

Other mutations, beside FAF1, are less likely to be causative for the cancer. EPHA3 was revealed as mutated in this cancer by DNA exome sequencing and RNASeq. EPHA3 is a receptor tyrosine kinase that is frequently mutated in lung cancer. Tumor-suppressive effects of wild-type EPHA3 can be overridden by dominant negative EPHA3 somatic mutations \[[@B20]\]. This mechanism is unlikely to play a role in this sarcoma as the detected mutation is located far N-terminally on the extracellular Ephrin binding domain not on the intracellular kinase domain.

FAF1 has been described to act as a tumor suppressor gene \[[@B21]\]. Its depletion due to chromosome breakage can affect prognosis in glioblastoma patients \[[@B22], [@B23]\]. Single nucleotide polymorphisms in FAF1 are associated with a risk for gastric cancer \[[@B24]\]. While numerous FAF1 mutations are associated with various cancers, none of these genetic changes in the TCGA database affects the amino acid position 181 ([Table 4](#tab4){ref-type="table"}).

The major upregulations identified in this tumor comprise muscle-specific gene products (transcription factors: CAAC binding; proteomics: transgelin, transgelin-2; RNA: anoctamin-4; and immunohistochemistry: smooth muscle actin) and calcium-regulating molecules (proteomics: calumenin, S100-A11, reticulocalbin-3, and 78 kD glucose-regulated protein). The muscle-specific gene products confirm this recurrent sarcoma as a leiomyosarcoma (the first tumor, distal to the site of the recurring one, had been diagnosed as an osteosarcoma). Calcium is one of the major second messengers in smooth muscle cells. Its uptake is regulated by potential-sensitive ion channels in the cell membrane and by the activities of various receptors. Calcium is stored in the sarcoplasmic reticulum, from where it can be released to facilitate actin-myosin interaction and tension generation. Phosphorylation of the myosin light chain by a calmodulin-regulated enzyme is important for contraction. The upregulation of gene products associated with migration and invasion (osteopontin, MMP1, vimentin, filamin-A, and *β*-actin) and gene products for extracellular matrix molecules and their modulators (fibronectin, collagen, ITGBL1, and MXRA5) reflects the invasive nature of this cancer.

The recurrence of a sarcoma after 14 years has two probable explanations, either it is due to a cancer predisposition syndrome based on a germ-line mutation (the age of the patient weakens this hypothesis) or the second tumor is a metastatic colony of the first that was reactivated after dormancy. The location of the sarcoma in the same extremity and proximal to a preceding mesenchymal cancer (and therefore in its natural path of dissemination) implied the probability that this was a relapse in a metastatic site. The different histologic assessment as osteosarcoma in the first occurrence and leiomyosarcoma as the second cancer does not necessarily negate that. Mixed histology \[[@B25], [@B26]\] and transdifferentiation \[[@B27]--[@B29]\] have been described for sarcomatous tumors. Of note, however, in this scenario osteosarcoma seems to more commonly follow leiomyosarcoma than precede it. Material from the first cancer of this patient was not accessible to us. It is very plausible that this could have been a mineralized leiomyosarcoma. In those tumors, the differential diagnosis from osteosarcoma can be difficult \[[@B30]\]. The extracompartmental location of the first tumor supports this interpretation.

On the molecular pathology level, sarcomas fall into two groups, comprising tumors with simple karyotypes (with pathogenetic translocations or specific genetic mutations) and tumors with very complex karyotypes (overt chromosome and genomic instability with numerous gains and losses) \[[@B31]\]. Some molecular alterations that lead to carcinogenesis can be defined in absolute terms. They include gain-of-function mutations or chromosome translocations that transform protooncogenes to oncogenes. However, other changes are relative to the normal tissue of origin, such as pathway overactivity or overexpression on the protein or RNA levels. We have combined the analysis of absolute changes (DNA exome sequence, RNA sequence) with the analysis of relative changes using skeletal muscle and bone as reference organs (protein-DNA array, 2D gel electrophoresis, and RNA expression levels). This choice was determined in part by tissue availability after surgery and was intended to aid in the distinction of osteosarcoma from myosarcoma. While a more accurate reference point for a leiomyosarcoma would have been smooth muscle, we believe that the comparison to striated muscle is sufficient to allow the assessment of tumor specific changes. We have measured RNA, DNA, and protein with various assays. Similar assessments in the future should also include chromosome analysis for possible translocations.

In the first-line defense against cancer, the gradual replacement of conventional chemotherapy with molecularly targeted agents has opened the possibility to tailor drug treatments to particular tumors. This transition necessitates the characterization of the molecular lesions that are causative for the transformation of healthy cells into cancerous cells, because drugs need to be matched with the underlying carcinogenic defect to be effective. An additional caveat, caused by unique genetic changes in the primary tumor, can affect drug transport and metabolism and needs to be taken into consideration. In this case, the RNA levels for genes that regulate transport and metabolism were extensively skewed in the tumor tissue as compared to muscle and bone (see [Table 3](#tab3){ref-type="table"}), implying potential challenges to chemotherapy. An advanced molecular treatment strategy for cancer will rely on the molecular definition of drug target, drug transport, and drug metabolism pharmacogenetics in the primary tumor. Consecutive to cancer dissemination, it will also require adjustments to account for the genetic changes in the metastases.

The cost of health care has been under increasing scrutiny. The treatment of cancer patients is expensive, in particular when hospitalization is required, and further in cases of end-of-life care. Avoidable expenditures are generated by suboptimal treatment decisions that result in low efficacy or high toxicity of anticancer regimens. Molecular medicine has the potential to preempt those problems and reduce wasteful spending. Yet, it requires the upfront cost of molecular cancer examination. The analysis performed in this study required about \$11,000.- in nonsalary expenses to perform. While it has not identified a drug target, it has specified possible confines for drug treatment. The costs for molecular analysis need to be weighed against the societal cost derived from lost productivity in the workforce, disrupted lives of families, and premature deaths. While currently limited drug options constitute the major constraint to the approach taken here, the foreseeable future will bring an increasing spectrum of molecularly targeted drugs along with faster and cheaper technologies for the molecular assessment of cancers. They will facilitate the clinical translation of our approach.
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![Osteosarcoma. (a) Whole body scan shows abnormally intense uptake of the radionuclide (Tc) within the middiaphysis of the right femur. No increased radionuclide uptake is seen anywhere else in the bony skeleton. (b) MRI scan displays an extensively abnormal signal in the diaphysis of the right femur. It is surrounded by soft tissue involvement. (c) Bone lesion displayed postoperatively.](SARCOMA2015-839182.001){#fig1}

![FAF1 structure. (a) A schematic of functional domains in FAF1 with annotations (adapted from \[[@B11]--[@B39]\]). There are two ubiquitin-like domains flanking the S181 site. The PDB structure 2DZM identifies the N-terminal one, while the C-terminal prediction is by sequence similarity. Whereas the mutation S181G is not expected to disrupt the protein structure per se, this amino acid has a high score as a possible phosphorylation site for a number of kinases involved in DNA damage repair. (b) Secondary structure prediction of FAF1. The residues around S181 appear unstructured.](SARCOMA2015-839182.002){#fig2}

![Transcription factor activation. Nuclear extracts from tumor, muscle, and bone were tested for DNA binding activity on a protein-DNA array. (a) Transcription factor binding that was high in all 3 tissues and is therefore considered constitutively active is circled in yellow (left to right, top to bottom: AhR/Amt, GATA1, GATA2, GATA1/2, HIF1, and HOXD8/9/10). Transcription factors that show high binding in the cancer, but not in muscle or bone, are circled in red (left to right, top to bottom: E2F1, AP3, LIII-BP, PAX6, ADD-1, and CCAC). (b) The functions of transcription factors that display high DNA binding in the cancer, but not in muscle or bone, are described.](SARCOMA2015-839182.003){#fig3}

![Protein overexpression. (a) 2D protein gel electrophoresis of lysates from muscle (upper left), tumor (upper right), and bone (bottom) in RIPA buffer. Red circles indicate the spots that were identified as overexpressed and were further analyzed by mass spectrometry. (b) Proteins identified in 2D gel electrophoresis as overexpressed in the tumor in comparison to muscle and bone were analyzed for their identity by mass spectrometry. The left column indicates the spot number corresponding to the 2D gel. The next column contains the protein name, followed by the accession number and a description of the protein function. The protein functions are grouped into structural, calcium homeostasis, and various others. (c) Western blot. 10 *μ*g lysates of tumor, muscle, and bone in RIPA buffer were loaded per lane and electrophoresed on 10% SDS-polyacrylamide minigels with reducing, denaturing sample buffer. After transfer to PVDF membranes, they were probed for markers of cancer progression, including osteopontin, CD44, STAT3, and phospho-STAT3. Antitubulin served as a loading control. (d) RNA levels corresponding to the proteins found to be affected in the sarcoma. With four exceptions in the tumor-bone comparison (gray font), upregulated proteins are associated with increased RNA levels. STAT3 is not increased on the protein or RNA level. The reduced level of RB1 expression is consistent with the elevated DNA binding activity of E2F1.](SARCOMA2015-839182.004){#fig4}

![Possible transforming pathway. The point mutation in FAF1 is believed to cause a loss of function (crossed out in red). This may lead to an overactivity of the WNT signaling pathway. Consistently, E2F1 (activated by LEF1) and*igf2bp1* (a transcriptional target of the WNT pathway) have been identified to be upregulated in the molecular analysis. In contrast to the negative regulator FAF1, IGF2BP1 is a positive regulator of NF-*κ*B activity. The overactivity of the NF-*κ*B pathway and the reduced efficacy of FAS signaling can be transforming.](SARCOMA2015-839182.005){#fig5}

###### 

DNA exome SNPs. The DNA exomes for tumor, muscle, and bone were sequenced. The results were filtered in the following order: (1) different genotype in tumor from muscle and bone, with muscle and bone being identical to each other, (2) delete mutations with low confidence (value of 20 or lower) in all 3 tissues, (3) delete unidentified genes, (4) delete mutations that are homozygous reference in the tumor, (5) delete mutations that have a MAF in dbSNP \>10%, (6) delete low impact and modifier mutations. The gene names are part of the key in the left column. In this column, results on bold font represent SNPs that were confirmed on the RNA level by RNASeq. The data files have been submitted to the NCBI short read archive (SRA) under the accession number SRP052797 (biosamples SAMN03316820, SAMN03316821, SAMN03316822).

  Key                            Chromosome   Position    Reference            Alternate   dbSNP ID     dbSNP MAF   ESP MAF (All)   ESP MAF (EA)   ESP MAF (AA)   Consensus impact   Bone/muscle genotype   Bone overall depth   Bone allele depths   Bone quality   Muscle overall depth   Muscle allele depths   Muscle quality   Tumor genotype   Tumor overall depth   Tumor allele depths   Tumor quality
  ------------------------------ ------------ ----------- -------------------- ----------- ------------ ----------- --------------- -------------- -------------- ------------------ ---------------------- -------------------- -------------------- -------------- ---------------------- ---------------------- ---------------- ---------------- --------------------- --------------------- ---------------
  **17_7479998_T\_EIF4A1**       17           7479998     C                    T           .            ---         ---             ---            ---            Moderate           0/0                    175                  184,0                99             103                    108,0                  99               0/1              133                   79,68                 99
  **3_89259200_T\_EPHA3**        3            89259200    C                    T           .            ---         ---             ---            ---            Moderate           0/0                    43                   45,0                 99             117                    123,0                  99               0/1              72                    30,48                 99
  **1_51204545_C\_FAF1**         1            51204545    T                    C           .            ---         ---             ---            ---            Moderate           0/0                    87                   91,0                 99             108                    113,0                  99               0/1              85                    66,27                 99
  **12_30834620_A\_IPO8**        12           30834620    C                    A           .            ---         ---             ---            ---            Moderate           0/0                    68                   71,2                 99             120                    126,0                  99               0/1              80                    70,18                 99
  **11_101834425_A\_KIAA1377**   11           101834425   G                    A           .            ---         ---             ---            ---            Moderate           0/0                    36                   37,1                 90             67                     70,0                   99               0/1              86                    31,63                 99
  **4_41682102_C\_LIMCH1**       4            41682102    G                    C           .            ---         0.000077        0              0.000227       Moderate           0/0                    71                   74,0                 99             96                     101,0                  99               0/1              153                   120,49                99
  **5_36985326_G\_NIPBL**        5            36985326    A                    G           .            ---         ---             ---            ---            Moderate           0/0                    6                    6,0                  18             35                     36,0                   81               0/1              20                    10,12                 99
  3_77623789_A\_ROBO2            3            77623789    AG                   A           .            ---         ---             ---            ---            High               0/0                    22                   NA                   54             29                     NA                     87               0/1              37                    NA                    99
  2_217300095_A\_SMARCAL1        2            217300095   ATTGCATCAACGTCGTGG   A           .            ---         ---             ---            ---            High               0/0                    95                   NA                   99             122                    NA                     99               0/1              99                    NA                    99
  2_152236045_T\_TAA_TNFAIP6     2            152236045   TA                   T/TAA       rs35060021   ---         ---             ---            ---            High               0/2                    19                   NA                   1              24                     NA                     57               0/1              17                    NA                    38
  3_52020669_T\_ACY1             3            52020669    G                    T           .            ---         ---             ---            ---            Moderate           0/0                    130                  136,0                99             86                     90,0                   99               0/1              80                    45,43                 99
  9_117130734_G\_AKNA            9            117130734   C                    G           .            ---         ---             ---            ---            Moderate           0/0                    27                   28,0                 78             30                     31,0                   90               0/1              50                    30,24                 99
  12_6030354_A\_ANO2             12           6030354     C                    A           .            ---         ---             ---            ---            Moderate           0/0                    101                  106,0                99             114                    120,0                  99               0/1              135                   104,45                99
  18_10487667_A\_APCDD1          18           10487667    G                    A           .            ---         ---             ---            ---            Moderate           0/0                    43                   45,0                 99             38                     40,0                   99               0/1              50                    38,16                 99
  7_34118560_C\_BMPER            7            34118560    G                    C           .            ---         ---             ---            ---            Moderate           0/0                    69                   72,0                 99             101                    106,0                  99               0/1              71                    63,14                 99
  15_24921273_T\_C15orf2         15           24921273    G                    T           .            ---         ---             ---            ---            Moderate           0/0                    12                   12,0                 36             38                     39,0                   99               0/1              26                    22,6                  99
  19_54483249_C\_CACNG8          19           54483249    T                    C           .            ---         ---             ---            ---            Moderate           0/0                    147                  154,0                99             103                    108,0                  99               0/1              152                   136,32                99
  10_16893265_C\_CUBN            10           16893265    G                    C           .            ---         ---             ---            ---            Moderate           0/0                    57                   60,0                 99             90                     94,0                   99               0/1              40                    34,10                 99
  7_148489854_C\_CUL1            7            148489854   A                    C           .            ---         ---             ---            ---            Moderate           0/0                    73                   76,0                 99             65                     68,0                   99               0/1              57                    42,21                 99
  17_41566894_C\_DHX8            17           41566894    G                    C           .            ---         ---             ---            ---            Moderate           0/0                    106                  111,0                99             88                     92,0                   99               0/1              124                   94,42                 99
  20_61512358_T\_DIDO1           20           61512358    G                    T           rs73304513   0.0417      0.045932        0.000838       0.135456       Moderate           0/0                    6                    0,0                  18             2                      0,0                    6                0/1              4                     0,0                   21
  16_23703526_A\_ERN2            16           23703526    G                    A           .            ---         ---             ---            ---            Moderate           0/0                    81                   85,0                 99             98                     103,0                  99               0/1              91                    60,41                 99
  3_197880164_G\_FAM157A         3            197880164   GCAGCAGCAA           G           .            ---         ---             ---            ---            Moderate           0/0                    21                   NA                   25             25                     NA                     1                0/1              31                    NA                    6
  14_45644287_G\_FANCM           14           45644287    A                    G           .            0.0009      ---             ---            ---            Moderate           0/0                    13                   13,0                 33             31                     32,0                   87               0/1              12                    10,2                  14
  1_89637524_C\_GBP7             1            89637524    G                    C           .            ---         ---             ---            ---            Moderate           0/0                    171                  179,0                99             201                    211,0                  99               0/1              206                   161,67                99
  7_42003933_C\_GLI3             7            42003933    G                    C           .            ---         ---             ---            ---            Moderate           0/0                    87                   91,0                 99             81                     85,0                   99               0/1              85                    61,32                 99
  17_4837170_T\_GP1BA            17           4837170     C                    T           .            ---         ---             ---            ---            Moderate           0/0                    16                   16,0                 45             9                      9,0                    15               0/1              11                    10,1                  1
  14_24635161_G\_IRF9            14           24635161    T                    G           .            ---         ---             ---            ---            Moderate           0/0                    66                   69,0                 99             43                     45,0                   99               0/1              36                    25,13                 99
  15_42133096_A\_JMJD7-PLA2G4B   15           42133096    G                    A           .            ---         ---             ---            ---            Moderate           0/0                    111                  116,0                99             75                     78,0                   99               0/1              80                    74,14                 92
  17_40271678_A\_KAT2A           17           40271678    G                    A           .            ---         ---             ---            ---            Moderate           0/0                    65                   68,0                 99             58                     61,0                   99               0/1              56                    30,32                 99
  8_73848894_G\_KCNB2            8            73848894    A                    G           .            ---         ---             ---            ---            Moderate           0/0                    15                   15,0                 33             24                     25,0                   66               0/1              30                    15,17                 99
  19_50827053_T\_KCNC3           19           50827053    C                    T           .            ---         ---             ---            ---            Moderate           0/0                    220                  231,0                99             136                    143,0                  99               0/1              160                   130,46                99
  17_21319069_A\_KCNJ12          17           21319069    G                    A           rs76265595   ---         ---             ---            ---            Moderate           0/0                    23                   24,1                 63             43                     43,4                   40               0/1              28                    25,5                  60
  12_53011932_C\_KRT73           12           53011932    T                    C           .            ---         ---             ---            ---            Moderate           0/0                    146                  153,0                99             157                    165,0                  99               0/1              159                   117,58                99
  X_75004584_A\_MAGEE2           X            75004584    C                    A           .            ---         ---             ---            ---            Moderate           0/0                    29                   30,0                 81             48                     50,0                   99               0/1              38                    26,16                 99
  5_140182157_A\_PCDHA3          5            140182157   G                    A           .            ---         ---             ---            ---            Moderate           0/0                    180                  189,0                99             153                    161,0                  99               0/1              150                   132,34                99
  15_42133096_A\_PLA2G4B         15           42133096    G                    A           .            ---         ---             ---            ---            Moderate           0/0                    111                  116,0                99             75                     78,0                   99               0/1              80                    74,14                 92
  10_96005840_C\_PLCE1           10           96005840    T                    C           .            ---         ---             ---            ---            Moderate           0/0                    81                   85,1                 99             73                     76,2                   99               0/1              87                    55,40                 99
  1_166816805_G\_POGK            1            166816805   C                    G           .            ---         ---             ---            ---            Moderate           0/0                    84                   88,0                 99             82                     86,0                   99               0/1              63                    49,20                 99
  12_111020739_T\_PPTC7          12           111020739   TCGC                 T           rs71083132   ---         ---             ---            ---            Moderate           0/0                    18                   NA                   30             14                     NA                     18               0/1              19                    NA                    10
  19_804293_A\_PTBP1             19           804293      C                    A           .            ---         ---             ---            ---            Moderate           0/0                    120                  126,1                99             71                     74,1                   99               0/1              75                    53,30                 99
  7_156451175_C\_RNF32           7            156451175   G                    C           .            ---         ---             ---            ---            Moderate           0/0                    55                   57,0                 99             67                     70,0                   99               0/1              59                    42,23                 99
  3_52020669_T\_RP11-155D18.11   3            52020669    G                    T           .            ---         ---             ---            ---            Moderate           0/0                    130                  136,0                99             86                     90,0                   99               0/1              80                    45,43                 99
  21_43838624_T\_UBASH3A         21           43838624    G                    T           .            ---         ---             ---            ---            Moderate           0/0                    70                   73,0                 99             45                     47,0                   99               0/1              89                    76,21                 99
  19_58773857_A\_ZNF544          19           58773857    G                    A           .            ---         ---             ---            ---            Moderate           0/0                    46                   48,0                 99             43                     45,0                   99               0/1              71                    51,26                 99
  5_16465723_C\_ZNF622           5            16465723    T                    C           .            ---         ---             ---            ---            Moderate           0/0                    17                   17,0                 39             14                     14,0                   33               0/1              27                    14,15                 99

###### 

RNA induced in the tumor. (a) Transcripts overexpressed in the tumor compared to muscle but not bone. (b) Transcripts overexpressed in the tumor compared to bone but not muscle. (c) Transcripts most abundantly overexpressed in the tumor compared to muscle and bone. (d) as (a) but limited to genes expressed at least at the level of 1 unit in the reference tissue (muscle or bone). (e) Altered expression of genes associated with NF-*κ*B activity. Analysis of RNASeq for the transcription factor NF-*κ*B and gene products that regulate its activity. RNA messages that are selectively associated with the TNF pathway to NF-*κ*B activation are marked with bold font. log~2~-fold change indicates the alteration in the tumor compared to muscle or bone (the respective columns indicate the expression level for each organ).

                                                                                                                       log~2~-fold change
  ------------------- ------------------------------------------------------------------------------------------------ --------------------
  Tumor over muscle                                                                                                     
  NRG1                Neuregulin 1                                                                                     9.909
  KSR2                Kinase suppressor of ras 2                                                                       9.675
  MMP13               Matrix metallopeptidase 13 (collagenase 3)                                                       9.528
  SPP1                Secreted phosphoprotein 1                                                                        9.098
  INHBA               Inhibin, beta A                                                                                  8.570
  COL11A1             Collagen, type XI, alpha 1                                                                       8.564
  MMP9                Matrix metallopeptidase 9 (gelatinase B, 92 kda gelatinase, 92 kda type IV collagenase)          8.552
  FBN2                Fibrillin 2                                                                                      8.495
  LRRC15              Leucine rich repeat containing 15                                                                8.429
  MMP11               Matrix metallopeptidase 11 (stromelysin 3)                                                       8.336
  E2F7                E2F transcription factor 7                                                                       8.314
  PRAME               Preferentially expressed antigen in melanoma                                                     8.179
  PTK7                PTK7 protein tyrosine kinase 7                                                                   7.996
  DSCAM               Down syndrome cell adhesion molecule                                                             7.761
  RGS4                Regulator of G-protein signaling 4                                                               7.633
  CNIH3               Cornichon homolog 3 (Drosophila)                                                                 7.632
  OR10V1              Olfactory receptor, family 10, subfamily V, member 1                                             7.610
  CEP55               Centrosomal protein 55 kda                                                                       7.583
  WNT5B               Wingless-type MMTV integration site family, member 5B                                            7.569
  CA12                Carbonic anhydrase XII                                                                           7.520
  GALNT5              UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5)   7.517

                                                                                                                    log~2~-fold change
  ----------------- ----------------------------------------------------------------------------------------------- --------------------
  Tumor over bone                                                                                                    
  ROS1              c-ros oncogene 1, receptor tyrosine kinase                                                      10.987
  GREM1             Gremlin 1                                                                                       10.604
  NPTX1             Neuronal pentraxin I                                                                            8.813
  GJB2              Gap junction protein, beta 2, 26 kDa                                                            8.597
  CREB3L1           cAMP responsive element binding protein 3-like 1                                                8.506
  KRT14             Keratin 14                                                                                      8.351
  SERPINE1          Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1   8.288
  HOXD10            Homeobox D10                                                                                    8.105
  ALPK2             Alpha-Kinase 2                                                                                  7.783
  POU3F2            POU class 3 homeobox 2                                                                          7.530
  POSTN             Periostin, osteoblast specific factor                                                           7.497
  NAA11             N(alpha)-acetyltransferase 11, NatA catalytic subunit                                           7.439
  STC2              Stanniocalcin 2                                                                                 7.434
  WNT5A             Wingless-type MMTV integration site family, member 5A                                           7.412
  IGFN1             Immunoglobulin-like and fibronectin type III domain containing 1                                7.387
  STC1              Stanniocalcin 1                                                                                 7.385
  FAM180A           Family with sequence similarity 180, member A                                                   7.315
  KRT17             Keratin 17                                                                                      7.305
  BBOX1             Butyrobetaine (gamma), 2-oxoglutarate dioxygenase (gamma-butyrobetaine hydroxylase) 1           7.277
  MAGEA1            Melanoma antigen family A, 1 (directs expression of antigen MZ2-E)                              7.267

                                                                                                                                                                               log~2~-fold change   
  ------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------- -------
  Tumor over bone/muscle                                                                                                                                                                             
  ANO4                     Anoctamin 4 (TMEM16D), transmembrane calcium-activated chloride channel, facilitates smooth muscle contraction                                      9.937                8.542
  SLCO1B3                  (OATP1B3) Solute carrier organic anion transporter family, member 1B3                                                                               9.569                9.760
  MARCH4                   Membrane-associated ring finger (C3HC4) 4, E3 ubiquitin ligase, located predominantly to the endoplasmic reticulum                                  9.538                7.406
  IGF2BP1                  Insulin-like growth factor 2 mRNA binding protein 1 binds to and stabilizes mRNA                                                                    9.440                9.631
  ADAMTS16                 ADAM metallopeptidase with thrombospondin type 1 motif, 16; zinc-dependent protease                                                                 9.260                8.450
  SOX11                    SRY (sex determining region Y)-box 11, important in brain development                                                                               9.178                9.954
  HAPLN1                   Hyaluronan and proteoglycan link protein 1 stabilizes aggregates of aggrecan and hyaluronan, giving cartilage its tensile strength and elasticity   8.951                8.142
  MUC15                    Mucin 15, cell surface associated                                                                                                                   8.801                7.992
  HOXB9                    Homeobox B9                                                                                                                                         8.773                7.378
  MAGEC2                   Melanoma antigen family C, 2                                                                                                                        8.693                8.884
  ST6GALNAC5               ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5                                       7.848                8.038
  C11orf41                 Chromosome 11 open reading frame 41                                                                                                                 7.781                8.141
  MMP1                     Matrix metallopeptidase 1 (interstitial collagenase)                                                                                                7.455                7.646

  Symbol                   Name                                                                    log~2~-fold change   log~2~-fold change           
  ------------------------ ----------------------------------------------------------------------- -------------------- -------------------- ------- --------
  Tumor over bone/muscle                                                                                                                              
  FN1                      Fibronectin 1                                                           7.328                6.293                6.457   19.860
  COL1A1                   Collagen, type I, alpha 1                                               6.768                3.706                5.868   11.934
  CCND1                    Cyclin D1                                                               5.595                3.958                5.098   9.637
  RGS1                     Regulator of G-protein signaling 1                                      5.118                1.056                4.653   2.533
  ITGBL1                   Integrin, beta-like 1 (with EGF-like repeat domains)                    5.071                3.177                3.895   12.415
  COL1A2                   Collagen, type I, alpha 2                                               4.852                8.756                4.910   14.503
  MXRA5                    Matrix-remodelling associated 5                                         4.834                1.352                4.631   2.685
  POSTN                    Periostin, osteoblast specific factor                                   4.513                5.870                7.497   1.267
  PLOD2                    Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2                      4.285                1.801                4.023   3.730
  COL5A2                   Collagen, type V, alpha 2                                               4.275                1.297                4.833   1.517
  COL3A1                   Collagen, type III, alpha 1                                             4.003                13.118               5.801   6.500
  SEMA3C                   Sema domain, immunoglobulin domain (Ig), short basic domain, secreted   3.954                1.164                4.215   1.675
  FBN1                     Fibrillin 1                                                             3.912                6.957                4.018   11.148
  AEBP1                    AE binding protein 1                                                    3.808                3.212                4.002   4.843
  SIK1                     Salt-inducible kinase 1                                                 3.805                1.219                3.566   2.484
  SERPINH1                 Serpin peptidase inhibitor, clade H (heat shock protein 47), member 1   3.706                1.652                4.145   2.098
  ANTXR1                   Anthrax toxin receptor 1                                                3.670                3.789                3.690   6.445

  Symbol          Name                                                                                                log~2~-fold change   log~2~-fold change                  
  --------------- --------------------------------------------------------------------------------------------------- -------------------- -------------------- -------------- --------------
  HELLS           Helicase, lymphoid-specific                                                                         5.315602             0.155898             −0.82713       20.2489
  **TNFRSF11A**   **Tumor necrosis factor receptor superfamily, member 11a, and NFKB activator**                      **3.017922**         **0.03091**          **1.400993**   **0.202453**
  NFKBID          Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, delta                 2.655352             0                    −1.47615       0.504341
  **TNFRSF25**    **Tumor necrosis factor receptor superfamily, member 25**                                           **2.432959**         **0.046388**         **0.163954**   **0.490795**
  NFKBIE          Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, epsilon               2.121015             0.062395             0.311441       0.43382
  **TNF**         **Tumor necrosis factor**                                                                           **1.847997**         **0**                **−1.42101**   **0.03733**
  **TNFRSF10D**   **Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain**       **1.754888**         **0.172968**         **−0.1757**    **1.183343**
  **TNFRSF1B**    **Tumor necrosis factor receptor superfamily, member 1B**                                           **1.473438**         **0.709902**         **−0.97011**   **6.729401**
  **TNFRSF10A**   **Tumor necrosis factor receptor superfamily, member 10a**                                          **1.411898**         **0.828219**         **0.357701**   **3.004386**
  NFKBIB          Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, beta                  1.193993             1.209816             0.46055        3.484692
  **TNFRSF10B**   **Tumor necrosis factor receptor superfamily, member 10b**                                          **1.094157**         **1.908597**         **0.425446**   **5.242006**
  **TNFRSF21**    **Tumor necrosis factor receptor superfamily, member 21**                                           **1.055762**         **3.882038**         **0.745815**   **8.305711**
  **TNFRSF1A**    **Tumor necrosis factor receptor superfamily, member 1A**                                           **0.875167**         **3.790938**         **−0.11707**   **13.0344**
  NFKBIZ          Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta                  0.575974             3.698951             0.344657       7.493136
  **RIPK1**       **Receptor (TNFRSF)-interacting serine-threonine kinase 1**                                         **0.494467**         **3.11749**          **−1.08854**   **16.1392**
  NKRF            NFKB repressing factor                                                                              0.475722             2.156087             −0.86397       9.434166
  NFKB1           Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1                                0.432959             2.054532             −0.65865       7.568586
  CHUK            Conserved helix-loop-helix ubiquitous kinase                                                        0.176126             2.961281             −1.20204       13.30333
  RELA            V-rel reticuloendotheliosis viral oncogene homolog A (avian)                                        0.013848             1.263837             0.287167       1.803044
  NFKB2           Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)                     −0.08641             0.312993             0.485882       0.360442
  NKAPP1          NFKB activating protein pseudogene 1                                                                −0.10692             0.825177             −0.99449       2.655392
  **TNFRSF10C**   **Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain**   **−0.152**           **0.064676**         **−5.56891**   **6.321515**
  NKIRAS2         NFKB inhibitor interacting Ras-like 2                                                               −0.60768             1.095135             −0.88758       2.299946
  NFKBIL1         Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1                 −0.8719              0.141933             −0.08357       0.140418
  NKIRAS1         NFKB inhibitor interacting Ras-like 1                                                               −0.87428             6.296399             1.467735       2.122983
  TANK            TRAF family member-associated NFKB activator                                                        −0.983               6.777124             −1.51908       16.95872
  NKAP            NFKB activating protein                                                                             −1.35735             14.22458             −0.78243       16.46287
  NFKBIA          Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha                 −1.85483             40.32743             −0.31802       23.95275
  NKAPL           NFKB activating protein-like                                                                        −5.57347             5.875743             −1.40215       0.534643

###### 

Deregulation of genes for drug disposition. Analysis of RNASeq for at least twofold overexpression (italic font) or underexpression (bold font) of genes for (a) transport and (b) metabolism in tumor compared to muscle and bone. For the export transporters (ABC transporters), only overexpression is considered relevant for drug resistance. Not shown in the table are the underexpressed genes (ABCA7, ABCA8, ABCA13, ABCB6, ABCB10, ABCC6, ABCC6P1, ABCC6P2, ABCC8, ABCC11, ABCD2, ABCG2, and ABCG5).

###### 

\(a\) Transport

  Gene ID   Symbol     Name                                                                             Tumor bone   Tumor muscle
  --------- ---------- -------------------------------------------------------------------------------- ------------ --------------
  650655    ABCA17P    ATP-binding cassette, subfamily A (ABC1), member 17, pseudogene                  −1.360       −*2.116*
  24        ABCA4      ATP-binding cassette, subfamily A (ABC1), member 4                               −*2.038*     −*2.802*
                                                                                                                     
  6555      SLC10A2    Solute carrier family 10 (sodium/bile acid cotransporter family), member 2       −1.962       **−2.112**
  345274    SLC10A6    Solute carrier family 10 (sodium/bile acid cotransporter family), member 6       −*2.623*     −*3.240*
  6563      SLC14A1    Solute carrier family 14 (urea transporter), member 1 (Kidd blood group)         **−3.074**   **−3.152**
  6565      SLC15A2    Solute carrier family 15 (H+/peptide transporter), member 2                      **−2.027**   **−2.152**
  6566      SLC16A1    Solute carrier family 16, member 1 (monocarboxylic acid transporter 1)           −1.401       −*2.170*
  117247    SLC16A10   Solute carrier family 16, member 10 (aromatic amino acid transporter)            −*2.113*     −*2.848*
  6567      SLC16A2    Solute carrier family 16, member 2 (monocarboxylic acid transporter 8)           −*3.242*     −*3.848*
  10786     SLC17A3    Solute carrier family 17 (sodium phosphate), member 3                            **−2.868**   **−2.959**
  6571      SLC18A2    Solute carrier family 18 (vesicular monoamine), member 2                         **−2.087**   **−2.194**
  6573      SLC19A1    Solute carrier family 19 (folate transporter), member 1                          **−2.099**   **−2.203**
  10560     SLC19A2    Solute carrier family 19 (thiamine transporter), member 2                        −1.820       −*2.548*
  80704     SLC19A3    Solute carrier family 19, member 3                                               **−3.331**   **−3.478**
  387775    SLC22A10   Solute carrier family 22, member 10                                              −*5.711*     −*6.085*
  9390      SLC22A13   Solute carrier family 22 (organic anion transporter), member 13                  −*2.623*     −*3.217*
  85413     SLC22A16   Solute carrier family 22 (organic cation/carnitine transporter), member 16       **−8.101**   **−7.299**
  51310     SLC22A17   Solute carrier family 22, member 17                                              −1.475       −*2.175*
  5002      SLC22A18   Solute carrier family 22, member 18                                              −*2.038*     −*2.722*
  6582      SLC22A2    Solute carrier family 22 (organic cation transporter), member 2                  −*4.793*     −*5.216*
  6581      SLC22A3    Solute carrier family 22 (extraneuronal monoamine transporter), member 3         −*2.554*     −*3.182*
  6583      SLC22A4    Solute carrier family 22 (organic cation/ergothioneine transporter), member 4    **−3.603**   **−3.776**
  151295    SLC23A3    Solute carrier family 23 (nucleobase transporters), member 3                     −*2.109*     −*2.848*
  10478     SLC25A17   Solute carrier family 25 (mitochondrial carrier), member 17                      −1.311       −*2.077*
  83733     SLC25A18   Solute carrier family 25 (mitochondrial carrier), member 18                      −1.846       −*2.570*
  788       SLC25A20   Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20        **−2.105**   **−2.207**
  89874     SLC25A21   Solute carrier family 25 (mitochondrial oxodicarboxylate carrier), member 21     **−2.962**   **−3.105**
  51312     SLC25A37   Solute carrier family 25, member 37                                              **−4.633**   **−4.866**
  51629     SLC25A39   Solute carrier family 25, member 39                                              **−2.585**   **−2.737**
  203427    SLC25A43   Solute carrier family 25, member 43                                              −1.325       −*2.088*
  65012     SLC26A10   Solute carrier family 26, member 10                                              −*3.896*     −*4.472*
  115111    SLC26A7    Solute carrier family 26, member 7                                               −*3.431*     −*4.018*
  116369    SLC26A8    Solute carrier family 26, member 8                                               **−5.354**   **−5.536**
  115019    SLC26A9    Solute carrier family 26, member 9                                               −1.623       −*2.419*
  11001     SLC27A2    Solute carrier family 27 (fatty acid transporter), member 2                      **−4.278**   **−4.487**
  64078     SLC28A3    Solute carrier family 28 (sodium-coupled nucleoside transporter), member 3       **−4.543**   **−4.812**
  222962    SLC29A4    Solute carrier family 29 (nucleoside transporters), member 4                     −1.962       **−2.045**
  81031     SLC2A10    Solute carrier family 2 (facilitated glucose transporter), member 10             −*2.532*     −*3.170*
  6518      SLC2A5     Solute carrier family 2 (facilitated glucose/fructose transporter), member 5     **−3.647**   **−3.821**
  55532     SLC30A10   Solute carrier family 30, member 10                                              **−3.547**   **−3.725**
  7782      SLC30A4    Solute carrier family 30 (zinc transporter), member 4                            −*2.832*     −*3.372*
  6569      SLC34A1    Solute carrier family 34 (sodium phosphate), member 1                            **−4.716**   **−4.941**
  340146    SLC35D3    Solute carrier family 35, member D3                                              **−5.662**   **−5.906**
  54733     SLC35F2    Solute carrier family 35, member F2                                              −1.433       −*2.170*
  206358    SLC36A1    Solute carrier family 36 (proton/amino acid symporter), member 1                 **−2.265**   **−2.345**
  285641    SLC36A3    Solute carrier family 36 (proton/amino acid symporter), member 3                 **−2.284**   **−2.393**
  54020     SLC37A1    Solute carrier family 37 (glycerol-3-phosphate transporter), member 1            **−2.112**   **−2.212**
  2542      SLC37A4    Solute carrier family 37 (glucose-6-phosphate transporter), member 4             **−2.117**   **−2.219**
  151258    SLC38A11   Solute carrier family 38, member 11                                              −*2.410*     −*3.085*
  55089     SLC38A4    Solute carrier family 38, member 4                                               −1.837       −*2.548*
  92745     SLC38A5    Solute carrier family 38, member 5                                               −1.994       **−2.152**
  91252     SLC39A13   Solute carrier family 39 (zinc transporter), member 13                           −1.301       −*2.070*
  23516     SLC39A14   Solute carrier family 39 (zinc transporter), member 14                           −*2.569*     −*3.188*
  29985     SLC39A3    Solute carrier family 39 (zinc transporter), member 3                            **−2.032**   **−2.152**
  283375    SLC39A5    Solute carrier family 39 (metal ion transporter), member 5                       −1.623       −*2.370*
  7922      SLC39A7    Solute carrier family 39 (zinc transporter), member 7                            −1.273       −*2.058*
  30061     SLC40A1    Solute carrier family 40 (iron-regulated transporter), member 1                  **−3.612**   **−3.796**
  84102     SLC41A2    Solute carrier family 41, member 2                                               −1.293       −*2.070*
  8501      SLC43A1    Solute carrier family 43, member 1                                               **−2.013**   **−2.152**
  57153     SLC44A2    Solute carrier family 44, member 2                                               **−2.047**   **−2.152**
  50651     SLC45A1    Solute carrier family 45, member 1                                               −*2.038*     −*2.722*
  146802    SLC47A2    Solute carrier family 47, member 2                                               −1.962       **−2.026**
  6521      SLC4A1     Solute carrier family 4, anion exchanger, member 1                               **−6.513**   **−6.453**
  57282     SLC4A10    Solute carrier family 4, sodium bicarbonate transporter, member 10               **−2.640**   **−2.753**
  83959     SLC4A11    Solute carrier family 4, sodium borate transporter, member 11                    −1.846       −*2.569*
  6508      SLC4A3     Solute carrier family 4, anion exchanger, member 3                               −1.261       −*2.045*
  8671      SLC4A4     Solute carrier family 4, sodium bicarbonate cotransporter, member 4              −*2.445*     −*3.113*
  9497      SLC4A7     Solute carrier family 4, sodium bicarbonate cotransporter, member 7              −*2.717*     −*3.307*
  6523      SLC5A1     Solute carrier family 5 (sodium/glucose cotransporter), member 1                 **−2.547**   **−2.705**
  159963    SLC5A12    Solute carrier family 5 (sodium/glucose cotransporter), member 12                −*4.753*     −*5.206*
  6527      SLC5A4     Solute carrier family 5 (low affinity glucose cotransporter), member 4           **−3.969**   **−4.249**
  6540      SLC6A13    Solute carrier family 6 (neurotransmitter transporter, GABA), member 13          −1.328       −*2.092*
  55117     SLC6A15    Solute carrier family 6 (neutral amino acid transporter), member 15              −1.623       −*2.333*
  388662    SLC6A17    Solute carrier family 6, member 17                                               −*2.038*     −*2.728*
  54716     SLC6A20    Solute carrier family 6 (proline IMINO transporter), member 20                   −1.697       −*2.433*
  6532      SLC6A4     Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4      **−2.512**   **−2.611**
  6534      SLC6A7     Solute carrier family 6 (neurotransmitter transporter, L-proline), member 7      −*2.623*     −*3.228*
  56301     SLC7A10    Solute carrier family 7, (neutral amino acid transporter, y+ system) member 10   **−3.421**   **−3.603**
  6547      SLC8A3     Solute carrier family 8 (sodium/calcium exchanger), member 3                     **−2.204**   **−2.309**
  285335    SLC9A10    Solute carrier family 9, member 10                                               −1.208       −*2.000*
  6549      SLC9A2     Solute carrier family 9 (sodium/hydrogen exchanger), member 2                    −*2.038*     −*2.706*
  9368      SLC9A3R1   Solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1        **−2.760**   **−2.846**
  9351      SLC9A3R2   Solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 2        −1.889       −*2.619*
  84679     SLC9A7     Solute carrier family 9 (sodium/hydrogen exchanger), member 7                    −*3.347*     −*3.935*
  10599     SLCO1B1    Solute carrier organic anion transporter family, member 1B1                      −*3.360*     −*3.977*
  28234     SLCO1B3    Solute carrier organic anion transporter family, member 1B3                      −*9.760*     −*9.569*
  6578      SLCO2A1    Solute carrier organic anion transporter family, member 2A1                      −*2.432*     −*3.096*
  28232     SLCO3A1    Solute carrier organic anion transporter family, member 3A1                      **−2.032**   **−2.152**
  353189    SLCO4C1    Solute carrier organic anion transporter family, member 4C1                      **−6.850**   **−6.611**

###### 

\(b\) Metabolism

  Gene ID   Symbol    Name                                                     Tumor bone   Tumor muscle
  --------- --------- -------------------------------------------------------- ------------ --------------
  1583      CYP11A1   Cytochrome P450, family 11, subfamily A, polypeptide 1   −1.623       −*2.396*
  1589      CYP21A2   Cytochrome P450, family 21, subfamily A, polypeptide 2   −1.962       **−2.036**
  1591      CYP24A1   Cytochrome P450, family 24, subfamily A, polypeptide 1   −*5.208*     −*5.577*
  1592      CYP26A1   Cytochrome P450, family 26, subfamily A, polypeptide 1   −*2.623*     −*3.257*
  1594      CYP27B1   Cytochrome P450, family 27, subfamily B, polypeptide 1   −1.846       −*2.585*
  339761    CYP27C1   Cytochrome P450, family 27, subfamily C, polypeptide 1   −*3.585*     −*4.178*
  1553      CYP2A13   Cytochrome P450, family 2, subfamily A, polypeptide 13   −1.962       **−2.035**
  1580      CYP4B1    Cytochrome P450, family 4, subfamily B, polypeptide 1    **−4.820**   **−5.065**
  66002     CYP4F12   Cytochrome P450, family 4, subfamily F, polypeptide 12   **−6.070**   **−6.195**
  8529      CYP4F2    Cytochrome P450, family 4, subfamily F, polypeptide 2    **−7.769**   **−7.060**
  4051      CYP4F3    Cytochrome P450, family 4, subfamily F, polypeptide 3    **−8.244**   **−7.491**
  11283     CYP4F8    Cytochrome P450, family 4, subfamily F, polypeptide 8    **−5.006**   **−5.270**
  260293    CYP4X1    Cytochrome P450, family 4, subfamily X, polypeptide 1    **−2.476**   **−2.580**
  9420      CYP7B1    Cytochrome P450, family 7, subfamily B, polypeptide 1    −*2.502*     −*3.170*
                                                                                            
  2326      FMO1      Flavin containing monooxygenase 1                        −*4.360*     −*4.859*
  2327      FMO2      Flavin containing monooxygenase 2 (nonfunctional)        **−4.074**   **−4.337**
  2328      FMO3      Flavin containing monooxygenase 3                        **−4.036**   **−4.309**
  388714    FMO6P     Flavin containing monooxygenase 6 pseudogene             **−2.569**   **−2.737**
                                                                                            
  493869    GPX8      Glutathione peroxidase 8 (putative)                      −*2.814*     −*3.371*
  2938      GSTA1     Glutathione S-transferase alpha 1                        −1.623       −*2.363*
  2939      GSTA2     Glutathione S-transferase alpha 2                        −*2.038*     −*2.741*
  2941      GSTA4     Glutathione S-transferase alpha 4                        −1.492       −*2.188*
  2953      GSTT2     Glutathione S-transferase theta 2                        −*4.682*     −*5.170*
  653689    GSTT2B    Glutathione S-transferase theta 2B (gene/pseudogene)     −*3.739*     −*4.307*
                                                                                            
  84779     NAA11     N(alpha)-acetyltransferase 11, NatA catalytic subunit    −*7.439*     −*7.996*
  9027      NAT8      N-acetyltransferase 8 (GCN5-related, putative)           **−2.769**   **−2.920**
                                                                                            
  7358      UGDH      UDP-glucose 6-dehydrogenase                              −*2.333*     −*3.018*
  55757     UGGT2     UDP-glucose glycoprotein glucosyltransferase 2           −1.604       −*2.271*
  10720     UGT2B11   UDP glucuronosyltransferase 2 family, polypeptide B11    **−3.586**   **−3.768**
  7367      UGT2B17   UDP glucuronosyltransferase 2 family, polypeptide B17    **−2.836**   **−2.959**
  54490     UGT2B28   UDP glucuronosyltransferase 2 family, polypeptide B28    **−3.132**   **−3.284**
  167127    UGT3A2    UDP glycosyltransferase 3 family, polypeptide A2         **−4.716**   **−4.907**

###### 

FAF1 mutations in various cancers. FAF1 mutations listed in the TCGA data base were identified without restriction to any type of cancer. For the location of the affected domains on the protein compare [Figure 2](#fig2){ref-type="fig"}.

  AA            Mutation   Cancer                                  Domain
  ------------- ---------- --------------------------------------- --------
  N4S           Missense   Cutaneous melanoma                       
  I10S          Missense   Stomach adenocarcinoma                  UBA
  E21^\*^       Nonsense   Cutaneous melanoma                      UBA
  E25K          Missense   Uterine endometrioid carcinoma          UBA
  V38_splice    Splice     Stomach adenocarcinoma                  UBA
  P86fs         FS del     Colorectal adenocarcinoma                
  G123_splice   Splice     Uterine endometrioid carcinoma          UB1
  P136H         Missense   Colorectal adenocarcinoma               UB1
  T147M         Missense   Brain lower grade glioma                UB1
  D149Y         Missense   Uterine endometrioid carcinoma          UB1
  L159V         Missense   Lung adenocarcinoma                     UB1
  K163N         Missense   Uterine endometrioid carcinoma          UB1
  L170F         Missense   Cutaneous melanoma                       
  G184_splice   Splice     Colorectal cancer                        
  Q187H         Missense   Stomach adenocarcinoma                   
  S214N         Missense   Colorectal adenocarcinoma               UB2
  R222I         Missense   Uterine endometrioid carcinoma          UB2
  E238D         Missense   Lung adenocarcinoma                     UB2
  P241S         Missense   Uterine endometrioid carcinoma          UB2
  T245A         Missense   Renal clear cell carcinoma              UB2
  M249V         Missense   Uterine endometrioid carcinoma          UB2
  E280K         Missense   Brain lower grade glioma                 
  G293^\*^      Nonsense   Colorectal cancer                        
  T300I         Missense   Colorectal adenocarcinoma                
  D305H         Missense   Lung adenocarcinoma                      
  E308Q         Missense   Lung adenocarcinoma                      
  A316V         Missense   Stomach adenocarcinoma                   
  K319fs        FS ins     Head and neck squamous cell carcinoma    
  R344G         Missense   Stomach adenocarcinoma                  UAS
  F353I         Missense   Cutaneous melanoma                      UAS
  L379V         Missense   Breast invasive carcinoma               UAS
  C396F         Missense   Cutaneous melanoma                      UAS
  S459^\*^      Nonsense   Uterine endometrioid carcinoma          UAS
  G469_splice   Splice     Glioblastoma multiforme                 UAS
  R509G         Missense   Lung squamous cell carcinoma             
  E510fs        FS del     Cutaneous melanoma                       
  R516C         Missense   Uterine endometrioid carcinoma           
  A534V         Missense   Stomach adenocarcinoma                   
  F537L         Missense   Stomach adenocarcinoma                   
  E551^\*^      Nonsense   Lung adenocarcinoma                      
  R554W         Missense   Colorectal cancer                        
  S582I         Missense   Lung adenocarcinoma                     UBX
  F585L         Missense   Uterine endometrioid carcinoma          UBX
  E587^\*^      Nonsense   Lung adenocarcinoma                     UBX
  A592V         Missense   Stomach adenocarcinoma                  UBX
  W610^\*^      Nonsense   Breast invasive carcinoma               UBX
  D611Y         Missense   Lung adenocarcinoma                     UBX
  E635fs        FS del     Brain lower grade glioma                UBX
  P640fs        FS del     Cutaneous melanoma                      UBX
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